Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

被引：1
|
作者：
Takamatsu, Hiroyuki [1 ]
Yoroidaka, Takeshi [1 ,2 ]
Yamashita, Takeshi [2 ]
Murata, Ryoichi [2 ]
Ueda, Mikio [2 ]
Nakao, Shinji [1 ]
Matsue, Kosei [3 ]
机构：
[1] Kanazawa Univ, Dept Hematol, Kanazawa, Ishikawa, Japan
[2] Keiju Med Ctr, Dept Internal Med, Nanao, Japan
[3] Kameda Med Ctr, Div Hematol Oncol, Dept Med, Kamogawa, Japan
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122398
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3083
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
    Efstathios Kastritis
    Ioannis V. Kostopoulos
    Evangelos Terpos
    Bruno Paiva
    Despina Fotiou
    Maria Gavriatopoulou
    Nikolaos Kanellias
    Dimitrios C. Ziogas
    Maria Roussou
    Magdalini Migkou
    Evangelos Eleutherakis-Papaiakovou
    Ioannis P. Trougakos
    Ourania Tsitsilonis
    Meletios A. Dimopoulos
    Blood Cancer Journal, 8
  • [42] Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
    Kastritis, Efstathios
    Kostopoulos, Ioannis V.
    Terpos, Evangelos
    Paiva, Bruno
    Fotiou, Despina
    Gavriatopoulou, Maria
    Kanellias, Nikolaos
    Ziogas, Dimitrios C.
    Roussou, Maria
    Migkou, Magdalini
    Eleutherakis-Papaiakovou, Evangelos
    Trougakos, Ioannis P.
    Tsitsilonis, Ourania
    Dimopoulos, Meletios A.
    BLOOD CANCER JOURNAL, 2018, 8
  • [43] Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance
    Rodriguez, Sara
    Goicoechea, Ibai
    Gemenetzi, Katerina
    Botta, Cirino
    Agathangelidis, Andreas
    Puig, Noemi
    Cedena, Maria Teresa
    Medina, Alejandro
    Valdes-Mas, Rafael
    Garces, Juan Jose
    Perez, Jose J.
    Burgos, Leire
    Calasanz, Maria Jose
    Alignani, Diego
    Vilas-Zornoza, Amaia
    Sarai, Sarvide
    Prosper, Felipe
    Martinez-Climent, Jose Angel
    Orfao, Alberto
    Garcia-Sanz, Ramon
    Ubieto, Ana Jimenez
    Lopez, Joaquin Martinez
    Lahuerta, Juan Jose
    Rosinol, Laura
    Blade, Joan
    Mateos, Maria-Victoria
    Chatzidimitriou, Anastasia
    San-Miguel, Jesus F.
    Paiva, Bruno
    BLOOD, 2020, 136
  • [44] Clinical validation of next-generation sequencing-based clonality assays for minimal residual disease tracking in multiple myeloma
    Lin, Chuanming
    Jian, Qijie
    Huang, Zoufang
    Xie, Shuiling
    Xin, Liuyan
    Wu, Haiyan
    Pang, Fei
    Liao, Changfeng
    Chen, Yijian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma
    Medina, Alejandro
    Jimenez, Cristina
    Puig, Noemi
    Sarasquete, Maria Eugenia
    Flores-Montero, Juan
    Garcia-Alvarez, Maria
    Prieto-Conde, Isabel
    Chillon, Carmen
    Alcoceba, Miguel
    Gonzalez-Calle, Veronica
    Gutierrez, Norma C.
    Jacobsen, Austin
    Vigil, Edgar
    Hutt, Kasey
    Huang, Ying
    Orfao, Alberto
    Gonzalez, Marcos
    Miller, Jeffrey
    Garcia-Sanz, Ramon
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2022, 146 (07) : 862 - 871
  • [46] Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients
    Oliva, Stefania
    Genuardi, Elisa
    Belotti, Angelo
    Frascione, Pio Manlio Mirko
    Galli, Monica
    Capra, Andrea
    Offidani, Massimo
    Vozella, Federico
    Zambello, Renato
    Auclair, Daniel
    Siniscalchi, Agostina
    Yesil, Jennifer
    Annibali, Ombretta
    Kirsch, Ilan M.
    Caltagirone, Simona
    Jacob, Allison P.
    Ballanti, Stelvio
    Palmas, Angelo D.
    Ledda, Antonio
    Corradini, Paolo
    Omede, Paola
    Cavo, Michele
    Musto, Pellegrino
    Boccadoro, Mario
    Gay, Francesca
    BLOOD, 2019, 134
  • [47] Role of clonoSEQ®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma
    Nooka, Ajay
    Bradley, Kyle
    Joseph, Nisha
    Hofmeister, Craig C.
    Dhodapkar, Madhav V.
    Boise, Larry H.
    Lonial, Sagar
    Li, Shiyong
    Kaufman, Jonathan L.
    BLOOD, 2020, 136
  • [48] Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
    Roshal, Mikhail
    SEMINARS IN HEMATOLOGY, 2018, 55 (01) : 4 - 12
  • [49] Evaluation of Hematopoietic Stem Cell Product As a New Site for Minimal Residual Disease By Next Generation Flow in Multiple Myeloma
    de Melo Santos, Herbert Henrique
    Ribeiro, Glaciano
    Santos, Allan de Souza
    Chaves, Marcos
    Leal, Joanna
    Santos, Juliana Andrade
    Almeida, Alessandro de M.
    Salvino, Marco Aurelio
    Santos, Mariane Melo
    Hungria, Vania
    Arruda, Maria da Gloria B.
    Crusoe, Edvan De Queiroz
    BLOOD, 2021, 138
  • [50] Cost-effectiveness of next-generation sequencing minimal residual disease testing during maintenance treatment for multiple myeloma.
    Carlson, Josh John
    Eckert, Benjamin
    Zimmerman, Marita
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345